Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psoriasis

- PMLiVE

Novartis’ Cosentyx cleared for psoriasis in Europe

First of the IL-17 inhibitor classof drug to receive European approval

- PMLiVE

UCB moves Cimzia into phase III trials for psoriasis

Firm collaborating with Dermira to test efficacy and safety of drug

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

- PMLiVE

Novartis’ Cosentyx beats Stelara in psoriasis study

Cosentyx achieved clearance in 70% of patients

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

Amgen and AZ’s psoriasis antibody beats Stelara in study

Brodalumab cleared all skin lesions in 37% compared to Stelara’s 18.5%

Novartis building

FDA panel backs Novartis’ secukinumab for psoriasis

Drug has outperformed Amgen’s Enbrel in clinical trials

Novartis building

Novartis’ secukinumab has ‘consistent’ activity in psoriasis

Reinforces data that suggests drug is more effective than Amgen’s Enbrel

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Lilly’s psoriasis candidate tops Enbrel in phase III trials

Ixekizumab on course for regulatory filing in first half of 2015

- PMLiVE

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

Will boost its pipeline prospects and inhaled device capabilities

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis

Data reinforces secukinumab's position among new generation of biologic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links